Gh Research Plc (GHRS) Stock Price, Quote & News

Company Profile

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candi...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 437 8334

Website: www.ghres.com

Address:

Joshua Dawson House, Dawson Street, Dublin, Ireland

Sailingsoon May. 11 at 9:29 AM

$GHRS

0 · Reply

Sailingsoon May. 7 at 5:29 PM

$GHRS Whats the point here following the trend of the segment ? Institutional try to get more shares for a good average, knowing what is coming ? They want get mine 😎🏴‍☠️🥊🎈

0 · Reply

STACKD0E May. 4 at 12:27 AM

$GHRS 🙃✨️

0 · Reply

kareem1988 May. 3 at 2:49 PM

4 STOCKS ABSOLUTELY DESTROYING IT — EYES ON MONDAY OPEN $DRTS Oncology biotech going nuclear, Japan approval locked in, ASCO pancreatic cancer data dropping soon and fresh off the DDW oral presentation, 52-week high just hit $8.80. Bulls loading up. $GHRS Psychedelic therapy play on a TEAR Trading ~$20.71, up huge off its $9.46 52-week low. Strong Buy consensus, avg analyst PT at $39.25. $LIQT Small cap tech flashing the strongest buy signals on momentum scanners right now 📡 5/6 conditions met, 88% confidence. Volume confirming. $MNTK Oversold RNG play that just beat EPS estimates, Upgraded to Strong Buy. Median PT of $2.43 vs current ~$1.29 = massive upside IF it breaks out. Market had its best April since 2020. Momentum doesn't stop at the weekend.

1 · Reply

SuperGreenToday May. 2 at 1:18 AM

$GHRS Share Price: $20.70 Contract Selected: Oct 16, 2026 $22.5 Calls Buy Zone: $1.36 – $1.68 Target Zone: $2.52 – $3.08 Potential Upside: 75% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Doozio May. 1 at 2:43 AM

$GHRS powerful 👀 faatch 💣 or 🌙 ONTO 🐒🍌🧠⏰♾️

0 · Reply

Merlintrader Apr. 27 at 10:19 AM

$CMPS FDA, Psychedelics and the New Hunt for Sympathy Plays: , $ATAI, $HELP, $DFTX and $GHRS

0 · Reply

Rome777 Apr. 26 at 2:27 AM

$LLY $ATAI $GHRS https://x.com/wallstsai/status/2048191743808733379?s=46

0 · Reply

Jumpmanz Apr. 25 at 3:36 AM

$CMPS $DFTX $ENVB $GHRS $PBM

0 · Reply

History101 Apr. 25 at 1:16 AM

$ENVB $CMPS $GHRS $DFTX $PBM bullish article https://www.zerohedge.com/markets/fda-grants-quick-review-psychedelic-drugs-first-approvals-could-come-soon-summer

0 · Reply

GH Research Announces Pricing of $117.5 Million Underwritten Offering

Apr 20, 2026, 2:05 PM EDT - 22 days ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX HELP

Apr 20, 2026, 10:45 AM EDT - 22 days ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI CMPS DFTX

2026-04-20T14:00:40.000Z - 23 days ago

GH Research ‘welcomes’ Executive Order to accelerate mental illness treatments

Apr 20, 2026, 9:00 AM EDT - 23 days ago

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Apr 20, 2026, 8:26 AM EDT - 23 days ago

Psychedelic stocks rally with Trump's support

ATAI CMPS DFTX

Apr 20, 2026, 8:18 AM EDT - 23 days ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI CMPS DFTX

Apr 20, 2026, 6:43 AM EDT - 23 days ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB HELP

2026-03-25T15:15:16.000Z - 6 weeks ago

GH Research announces publication of Phase 2b results for mebufotenin

Mar 25, 2026, 11:10 AM EDT - 6 weeks ago

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

2026-03-10T11:01:34.000Z - 2 months ago

GH Research price target raised to $34 from $29 at Guggenheim

2026-03-06T10:46:32.000Z - 2 months ago

GH Research price target raised to $42 from $39 at Citizens

2026-03-05T12:10:05.000Z - 2 months ago

GH Research reports FY25 EPS (79c), consensus (82c)

Mar 5, 2026, 7:00 AM EST - 2 months ago

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

2026-01-29T15:30:42.000Z - 3 months ago

Psychedelic: Analyst raises Compass, Definium, GH Research price targets

CMPS DFTX ENVB INSM IXHL PBM

2026-01-23T19:25:14.000Z - 3 months ago

GH Research price target raised to $40 from $33 at RBC Capital

2026-01-06T12:46:46.000Z - 4 months ago

GH Research price target raised to $29 from $19 at Needham

2026-01-06T11:25:40.000Z - 4 months ago

GH Research price target raised to $39 from $35 at Canaccord

2026-01-05T12:12:13.000Z - 4 months ago

GH Research to seek FDA alignment on Phase 3 program replicating Phase 2b design

2026-01-05T12:05:34.000Z - 4 months ago

GH Research says FDA lifts clinical hold on GH001

2026-01-05T12:05:18.000Z - 4 months ago

GH Research: Phase 3 initiation targeted for 2026

Jan 5, 2026, 7:00 AM EST - 4 months ago

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

Jan 2, 2026, 4:01 PM EST - 4 months ago

GH Research to Announce IND Status for GH001

Nov 6, 2025, 7:00 AM EST - 6 months ago

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 9, 2025, 7:00 AM EDT - 7 months ago

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

Aug 7, 2025, 7:00 AM EDT - 9 months ago

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 23, 2025, 8:00 AM EDT - 10 months ago

GH Research Announces Global Pivotal Program Plans and Further Development Updates

Jun 20, 2025, 1:00 PM EDT - 11 months ago

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

May 15, 2025, 7:00 AM EDT - 1 year ago

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

May 8, 2025, 7:00 AM EDT - 1 year ago

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

Feb 27, 2025, 7:00 AM EST - 1 year ago

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 4, 2025, 8:52 PM EST - 1 year ago

GH Research Announces Pricing of $150 Million Public Offering

Feb 3, 2025, 4:03 PM EST - 1 year ago

GH Research Announces Proposed Public Offering

Feb 3, 2025, 8:00 AM EST - 1 year ago

GH Research Transcript: Status Update

Feb 3, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Jan 31, 2025, 4:01 PM EST - 1 year ago

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Jan 10, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Nov 14, 2024, 7:00 AM EST - 1 year ago

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 3, 2024, 7:05 AM EDT - 1 year ago

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Sep 3, 2024, 7:00 AM EDT - 1 year ago

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

May 3, 2024, 7:00 AM EDT - 2 years ago

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Feb 29, 2024, 7:00 AM EST - 2 years ago

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Jan 18, 2024, 4:30 PM EST - 2 years ago

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Nov 9, 2023, 4:45 PM EST - 2 years ago

GH Research Reports Third Quarter Financial Results and Provides Business Updates

Sep 29, 2023, 4:45 PM EDT - 2 years ago

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

Aug 23, 2023, 7:00 AM EDT - 2 years ago

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023, 7:30 AM EDT - 3 years ago

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

Mar 2, 2023, 7:00 AM EST - 3 years ago

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

Jan 9, 2023, 7:30 AM EST - 3 years ago

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Nov 10, 2022, 7:05 AM EST - 3 years ago

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

Aug 23, 2022, 7:00 AM EDT - 4 years ago

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

May 18, 2022, 7:00 AM EDT - 4 years ago

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

Mar 28, 2022, 7:04 AM EDT - 4 years ago

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

Dec 6, 2021, 7:10 AM EST - 4 years ago

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

Sep 23, 2021, 5:25 PM EDT - 5 years ago

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

Jun 25, 2021, 1:23 PM EDT - 5 years ago

7 Companies Go Public Today. What Investors Need to Know.

ELEV MCW TKNO ACXP

Sailingsoon May. 11 at 9:29 AM

$GHRS

0 · Reply

Sailingsoon May. 7 at 5:29 PM

$GHRS Whats the point here following the trend of the segment ? Institutional try to get more shares for a good average, knowing what is coming ? They want get mine 😎🏴‍☠️🥊🎈

0 · Reply

STACKD0E May. 4 at 12:27 AM

$GHRS 🙃✨️

0 · Reply

kareem1988 May. 3 at 2:49 PM

1 · Reply

SuperGreenToday May. 2 at 1:18 AM

0 · Reply

Doozio May. 1 at 2:43 AM

$GHRS powerful 👀 faatch 💣 or 🌙 ONTO 🐒🍌🧠⏰♾️

0 · Reply

Merlintrader Apr. 27 at 10:19 AM

$CMPS FDA, Psychedelics and the New Hunt for Sympathy Plays: , $ATAI, $HELP, $DFTX and $GHRS

0 · Reply

Rome777 Apr. 26 at 2:27 AM

$LLY $ATAI $GHRS https://x.com/wallstsai/status/2048191743808733379?s=46

0 · Reply

Jumpmanz Apr. 25 at 3:36 AM

$CMPS $DFTX $ENVB $GHRS $PBM

0 · Reply

History101 Apr. 25 at 1:16 AM

$ENVB $CMPS $GHRS $DFTX $PBM bullish article https://www.zerohedge.com/markets/fda-grants-quick-review-psychedelic-drugs-first-approvals-could-come-soon-summer

0 · Reply

ChartGuysDan Apr. 24 at 4:36 PM

Fun chat with @PsychedVantage talking charts and fundamentals for the sector's main leaders: https://youtu.be/kjF5opQryMU $CMPS $ATAI $DFTX $GHRS $HELP

0 · Reply

Jackie_O_ Apr. 23 at 4:27 PM

$DFTX $CMPS $ATAI These are my picks for vouchers. I also think $GHRS is a possibility, but it's very illiquid. Good luck to all longs! 🍀

4 · Reply

ChristopherMcC Apr. 23 at 12:32 PM

$HELP $DFTX $CMPS money's on comp360 dt120 and hpl003 for CNPVs. $GHRS for wave 2. Usona and Reunion Neuro dark horse possibilities. Lykos low end contender, not likely.

1 · Reply

RunnerSignals Apr. 20 at 7:41 PM

regulatory risk just got repriced $CMPS $ATAI $GHRS $ENVB this is timeline compression not hype flows moving before approvals not after

1 · Reply

JuliusW Apr. 20 at 2:53 PM

$ATAI $GHRS $HELP $DFTX well done atai and ghrs.

1 · Reply

EliteTradingGoat Apr. 20 at 1:48 PM

$GHRS OOOOUUTT +31%

0 · Reply

topstockalerts Apr. 20 at 1:29 PM

$GHRS solid action

0 · Reply

stockanalysis_ Apr. 20 at 1:18 PM

Psychedelics companies jump on Trump order: President Trump signed an executive order greenlighting faster psychedelic drug research, sending shares surging 8-86% premarket for Psyence (PBM), Atai (ATAI), Compass Pathways ($CMPS), Definium ($DFTX), Enveric ($ENVB), GH Research ($GHRS), and Cybin ($HELP). https://stockanalysis.com/market-bullets/2026-04-20/?ref=saveontrading

0 · Reply

kylevallans Apr. 20 at 1:17 PM

Psychedelics companies jump on Trump order: President Trump signed an executive order greenlighting faster psychedelic drug research, sending shares surging 8-86% premarket for Psyence ($PBM), Atai ($ATAI), Compass Pathways ($CMPS), Definium (DFTX), Enveric (ENVB), GH Research ($GHRS), and Cybin ($HELP). https://stockanalysis.com/market-bullets/2026-04-20/?ref=saveontrading

0 · Reply

topstockalerts Apr. 20 at 12:15 PM

Pre Market Top Gainers PT2 $ATAI $CMPS $JTAI $SKYQ $GHRS

0 · Reply

BreakoutsHappen Apr. 20 at 11:32 AM

On Saturday, April 18, President Trump signed an executive order directing multiple federal agencies to accelerate psychedelic research and expand access. It reverses a White House position from October, when an earlier voucher allocation to Compass Pathways had been pulled under political pressure. By Monday's pre-market, the four most institutionally tracked names in the space — $ATAI, $CMPS, $GHRS, and $DFTX — were all higher, with CMPS up roughly twenty-five percent, ATAI up twenty-three, and GHRS up seventeen. https://breakoutshappen.com/stock-news/psychedelic-stocks-after-the-executive-order-a-sector-re-rating-in-motion

0 · Reply

Market Cap	1.32B
Revenue (ttm)	0.00
Net Income (ttm)	-48.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	94,900
Avg Vol	225,760
Day's Range	N/A - N/A
Shares Out	62.03M
Stochastic %K	63%
Beta	1.27
Analysts	Strong Sell
Price Target	$39.25